Haleon reported 2.6% organic sales growth for its third quarter: 2.1% from price and 0.5% from volume/mix. Revenue landed 2% below the FactSet consensus. Management lowered guidance for full-year organic sales growth to 2.5% from 4%. Shares were down 15% midday on Oct. 29.
HLN is trading within a range we consider fairly valued.
Price
GBX346.70
Fair Value
LOCK|@q
Uncertainty
LOCK|>?!$W
1-Star Price
LOCK|#.&R
5-Star Price
LOCK|P.s!
Economic Moat
LOCK|Gf
Capital Allocation
LOCK|>!J?!<$
Bulls Say, Bears Say
Bulls
We expect Haleon, with financial and operational independence, to bolster its portfolio through product innovation and tuck-in acquisitions and expand the strong foothold it has in the consumer self-care industry.
Bears
Personalization of health paves the way for smaller niche players to carve out their shares of the market with bespoke offerings, and Haleon will have a tough time fighting for these areas given the difficulty of catering to these consumers with their megabrands.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.